Enjoy complimentary customisation on priority with our Enterprise License!
The global tyrosine kinase inhibitors market size is estimated to grow by USD 24.22 billion at a CAGR of 8.42% between 2023 and 2028. The market is experiencing growth driven by several key factors. Tyrosine kinase inhibitors are increasingly popular due to their high target affinity and specificity, making them effective in treating various cancers with fewer side effects compared to traditional chemotherapy. Additionally, the rising availability of patient assistance programs is improving access to these treatments, particularly for individuals with limited financial resources. The increasing prevalence of cancer worldwide is also contributing to market growth, driving the demand for effective and targeted therapies. These factors collectively underscore the importance of innovative treatments and supportive programs in addressing the global burden of cancer.
The market growth for tyrosine kinase inhibitors, including BRAF Kinase Inhibitors and ROS1 Inhibitors, is primarily fueled by their high target specificity and affinity. Multiple therapies approved for various cancers exist, yet many cause adverse effects, reducing patient adherence. Chemotherapy and standard treatments for advanced cancers result in severe side effects such as bone marrow suppression and diarrhea. Strategic alliances among market players drive growth, responding to the increasing prevalence of cancer. Tyrosine kinase inhibitors stand out as reliable options for cancer and age-related diseases like retinal vein occlusion. Consequently, numerous companies focus on their development and marketing. Given the substantial costs of drug development, players enter partnerships to share expenses. These inhibitors target signal transduction cascades, impacting cell proliferation, differentiation, cycle, and apoptosis. This approach extends to addressing fibrosis, diabetes, and other conditions, making tyrosine kinase inhibitors pivotal in healthcare systems. Market forecasting and analysis reports underscore their significance, aligning with market trends.
To learn more about this report, Download Report Sample
The market share growth by the offline segment will be significant during the forecast period. The offline segment includes wholesalers, distributors, and retailers that are responsible for the supply of pharmaceutical drugs, including tyrosine kinase inhibitors drugs, to hospitals, clinics, and pharmacies. These intermediaries work hand in hand with pharmaceutical manufacturers to ensure that tyrosine kinase inhibitors are made available to patients in need.
Get a glance at the market contribution of various segments Download PDF Sample
The offline segment was valued at USD 24.71 billion in 2018. Wholesalers are the first point of contact for manufacturers of tyrosine kinase inhibitor drugs and are responsible for distributing them to local distributors. Additionally, retailers, including pharmacies and hospitals, are the final link in the supply chain in offline distribution channels. Also, pharmacies are the most common type of retailer, and they usually stock a broad range of tyrosine kinase inhibitors to cater to the needs of different patients. Thus, such factors are expected to propel the growth of the offline segment of the market during the forecast period.
Receptor tyrosine kinase inhibitors (RTKIs) are more in number when compared with non-receptor tyrosine kinase inhibitors (nRTKIs). Hence, these therapeutics are used in the treatment of various diseases. This segment includes blockbuster drugs such as EYLEA, AVASTIN, and LENVIMA, which witnessed high sales in 2021. For instance, EYLEA generated USD 6,265 million in sales revenue in 2022, while AVASTIN generated USD 2,354.78 million in revenue in the same year. The increasing sales of such drugs, coupled with a strong pipeline along with late-stage molecules and recent drug approvals, are expected to drive the growth of this segment during the forecast period.
Non-receptor tyrosine kinase inhibitors (nRTKIs) are a class of pharmaceuticals designed to impede the activity of non-receptor tyrosine kinases, which are enzymes important in intracellular signaling pathways regulating cell growth, differentiation, and survival. Unlike receptor tyrosine kinases (RTKs) that are located on cell membranes, non-receptor tyrosine kinases operate within the cell. In the global market, nRTKIs represent an essential subset of targeted therapies primarily used in cancer treatment. Nowadays, the market has some approved therapies in this segment, such as GLEEVEC, SPRYCEL, IMBRUVICA, and TASIGNA. Thus, increasing developments of new non-receptor are projected to boost the growth of the nRTKIs segment of the market during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional market growth and trends that will shape the market during the forecast period. The growth of the TKIs market in North America is attributed to factors such as the high prevalence rate of cancer and the high unmet need for effective medications. They are attracting extensive R&D in North America due to their high target affinity and specificity. Moreover, the presence of major oncology companies in the region is resulting in a robust pipeline. Late-stage molecules from the pipeline are expected to be launched during the forecast period, which will also support the growth of the market in North America. The US is the major revenue contributor to the market in this region, as it is a hub of pharmaceutical companies. The per capita income of countries such as the US and Canada is high, which allows the population to spend more on healthcare. Thus, such factors are expected to propel the growth of the market in North America during the forecast period.
The market is vital in the treatment of various cancers, including Chronic Myeloid Leukemia (CML), Lung Cancer, Breast Cancer, and Renal Cell Cancer. Key drugs like Imatinib have revolutionized cancer treatment, leading to significant advances in patient outcomes. Ongoing clinical trials and research activities continue to expand the frontiers of this market, driving investment in new tyrosine kinase inhibitors. In the context of breast cancer, these inhibitors target cell differentiation, the cell cycle, and cell apoptosis, showing promise in molecular modeling and drug development. The market's growth is propelled by the increasing understanding of cancer biology and the development of novel therapies in the tyrosine kinase inhibitor drug class.
The high target affinity and specificity of tyrosine kinase inhibitors is the key factor driving market growth. There are several approved therapies for various types of cancers. However, most of the available therapies have adverse effects, which reduce the patient's adherence to treatments. For instance, chemotherapy and the existing standard of care (SoC) treatments for advanced cancers cause severe adverse effects such as bone marrow suppression, diarrhea, and alopecia. Similarly, surgery and radiation therapy are not useful in recurrent cancers.
Additionally, they can be an effective option for cancer treatment. They inhibit the activity of the enzyme tyrosine kinase. These drugs work directly on the target. Hence, their efficacy is higher than conventional treatments. Moreover, these drugs stabilize tumor progression, and the associated side effects are very few compared with cytotoxic chemotherapy drugs. Thus, such factors will drive the growth of the global market during the forecast period.
Strategic alliances among market players is the primary trend shaping growth. The growing prevalence of various diseases increases the demand for innovative therapeutics. Align with market trends and analysis, tyrosine kinase inhibitors therapeutics are one of the most reliable therapeutic options for the treatment of cancer and age-related diseases like retinal vein occlusion (RVO), which occurs when a blood clot blocks the retinal vein. Thus, many companies are associated with developing and marketing these drugs. Considering the high cost involved in the entire drug development and commercialization cycle, market players are entering various deals to share the cost.
Consequently, such strategic alliances, partnerships, and collaborations help market players reach out to a larger geographical area, expand their product portfolio, and get a better return on investment (ROI) as the products are co-developed and marketed. Hence, key market players are expected to continue exploring strategic ways to tap significant opportunities, which will drive market growth during the forecast period.
The high cost of currently available tyrosine kinase inhibitors is a challenge that affects market growth. The treatment cost is one of the major challenges faced by cancer patients. Many tyrosine kinase inhibitor therapeutics are used in combination with substitutes such as surgery and radiation therapy, which increases the cost of the treatment. The high cost of cancer treatment is mainly due to hospitalization, laboratory tests, and the administration of novel drugs therapeutics.
Moreover, the treatment cost of tyrosine kinase inhibitors therapeutics depends on the stage of cancer. The advanced or metastatic stage is very severe. In developing and underdeveloped countries, the cost of tyrosine kinase inhibitor treatment is very high. Thus, such high treatment costs reduce patient adherence to treatment, which is expected to impede the growth of the market in focus during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Market Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market research and growth and information about 20 market companies, including:
Novartis AG: The company offers tyrosine kinase inhibitors such as Scemblix, with novel mechanism of action, for adult patients with chronic myeloid leukemia.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024 to 2028, as well as historical data from 2018 to 2022 for the following segments.
Idiopathic Pulmonary Fibrosis (IPF) Market: Idiopathic Pulmonary Fibrosis (IPF) Market by Route of Administration, Drug Class, and Geography - Forecast, and Analysis
Chronic Myelogenous Leukemia Therapeutics Market: Chronic Myelogenous Leukemia Therapeutics Market by Product and Geography - Forecast and Analysis
Multiple Sclerosis Market in US: Multiple Sclerosis Market in US Growth, Size, Trends, Analysis Report by Type, Application, Region, and Segment Forecast
The market is at the forefront of cancer treatment, targeting crucial pathways in cell division and signaling in cancerous cells. Key players like DDR1 kinase inhibitors and EGFR TKIs have shown promise in treating various cancers, including Acute lymphoblastic leukemia (ALL) and Gastrointestinal tumors. Advances in artificial intelligence and drug discovery techniques, such as Insilico Medicine and generative adversarial networks (GANs), are revolutionizing the field, aiding in the identification of new therapeutic targets. However, challenges like the lack of qualified personnel and development costs remain. Market trends suggest a shift towards organic growth strategies and the development of new drugs like Osimertinib and Asciminib, both with Breakthrough Therapy designation (BTD), indicating the market's commitment to innovation in tackling cancer and inflammation-related diseases.
Furthermore, the market is a critical sector in cancer treatment, targeting aberrant cell signaling pathways that drive cancer growth. With rising cancer cases worldwide, the demand for effective therapies has intensified. Key players like BCR-ABL TKIs have revolutionized the treatment of certain cancers, particularly chronic myeloid leukemia. However, challenges such as development costs and market pricing persist, influencing market dynamics. The market is also impacted by broader healthcare trends, including the growing focus on personalized medicine and the role of biotechnology in drug development. Market analysis, including PEST analysis and market trend analysis, highlights the need for strategic planning to navigate challenges and capitalize on opportunities. As the market evolves, inorganic growth strategies like mergers and acquisitions play a pivotal role in shaping its future landscape.
Market Scope |
|
Report Coverage |
Details |
Page number |
164 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 8.42% |
Market Growth 2024-2028 |
USD 24.22 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
7.96 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 39% |
Key countries |
US, Canada, Germany, UK, and China |
Competitive landscape |
Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Danaher Corp., Deciphera Pharmaceuticals Inc., Eisai Co. Ltd., Eli Lilly and Co., Exelixis Inc., F. Hoffmann La Roche Ltd., Johnson and Johnson, Merck KGaA, Novartis AG, Pfizer Inc., Puma Biotechnology Inc., Rigel Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., and Tokyo Chemical Industry Co. Ltd. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the market forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.